DMAC
DiaMedica Therapeutics Inc.
$6.32
-3.22%
2026-05-08
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Key Fundamentals
Forward P/E
-7.70
EPS (TTM)
$-0.71
ROE
-86.5%
Profit Margin
0.0%
Debt/Equity
0.45
Price/Book
6.17
Beta
1.08
Market Cap
$347.0M
Avg Volume (10D)
166K
Recent Breakout Signals
No recent breakout signals detected for DMAC.
Recent Price Range (60 Days)
60D High
$9.04
60D Low
$5.71
Avg Volume
194K
Latest Close
$6.32
Get breakout alerts for DMAC
Sign up for Breakout Scanner to receive daily notifications when DMAC triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
DiaMedica Therapeutics Inc. (DMAC) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors DMAC daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. DMAC operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.